KATHRYN ELLIOTT: Open Payments
NPI 1023109089 · OXFORD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,123 in 68 payments from 16 companies in 2025. Trend: 2023 $1,620 · 2024 $1,030 · 2025 $1,123
Food & beverage: $1,123
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $229 |
| Lilly USA, LLC | 16 | $196 |
| Novo Nordisk Inc | 9 | $165 |
| Otsuka America Pharmaceutical, Inc. | 4 | $97 |
| AstraZeneca Pharmaceuticals LP | 6 | $94 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $65 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $54 |
| Astellas Pharma US Inc | 3 | $51 |
| Daiichi Sankyo Inc. | 1 | $20 |
Products named: UBRELVY, MOUNJARO, Ozempic, REXULTI, QULIPTA, JARDIANCE, Kerendia, XIFAXAN.
Industry payments across MS — which companies pay providers there.
